SARS-CoV-2 Serological Prevalence among General Population in India: A Short Summary from A Nationwide Sero-Epidemiological Study

Puneet Misra¹, Suprakash Mandal²*, Shashi Kant¹, Randeep Guleria¹, Sanjay K Rai², Surekha Kishore³, Subrata Baidya⁴, Arvind Kumar Singh⁵, Palanivel Chinnakali⁶, Guruprasad R Medigeshi⁷, Partha Haldar⁸, Mohan Bairwa⁹, Kapil Yadav¹⁰

Affiliation:
¹Professor, Centre for Community Medicine, All India Institute of Medical Sciences, New Delhi 110029, India
²Senior Resident, Centre for Community Medicine, All India Institute of Medical Sciences, New Delhi 110029, India
³Professor and Head, Centre for Community Medicine, All India Institute of Medical Sciences, New Delhi 110029, India
⁴Director, All India Institute of Medical Sciences, New Delhi 110029, India
⁵Professor, Centre for Community Medicine, All India Institute of Medical Sciences, New Delhi 110029, India
⁶Director, All India Institute of Medical Sciences, Gorakhpur-273008, India
⁷Professor and Head, Department of Community Medicine, Agartala Government Medical College, Agartala-799006, India
⁸Assistant Professor, Department of Community and Family Medicine, All India Institute of Medical Sciences, Bhubaneshwar, Odisha-751019, India
⁹Associate Professor, Department of Community Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry-605006, India
¹⁰Professor, Translational Health Science and Technology Institute, Faridabad-121001, India
¹¹Associate Professor, Centre for Community Medicine, All India Institute of Medical Sciences, New Delhi 110029, India
¹²Assistant Professor, Centre for Community Medicine, All India Institute of Medical Sciences, New Delhi 110029, India
¹³Additional Professor, Centre for Community Medicine, All India Institute of Medical Sciences, New Delhi 110029, India

*Corresponding Author
Dr. Suprakash Mandal, Senior Resident, Centre for Community Medicine, All India Institute of Medical Sciences, New Delhi 110029, India

Keywords: SARS-CoV-2; Antibody; Vaccination; Sero-epidemiological

Introduction

Antibody prevalence against SARS-CoV-2 remains one of the most important evidence to assess the extent of infection, portion of susceptible population, fraction of symptomatic-asymptomatic infection especially in young age group [1]. Till now several study has been conducted in different part of India. As per the nationwide seroprevalence study done in May-June, 2020 among 28,000 individual reported a prevalence of 0.73% [2]. The second seroprevalence study conducted from Aug 18 and Sept 20, 2020, among 29082 individuals from 15613 households reported 6.6% prevalence [3]. These study were during and after the first wave in India.

Methodology

We conducted this multi-centric population based sero-epidemiological study from March to August of 2021 during the ongoing second wave. The study was conducted among all age group above one year age in five study sites across India. The sites were Delhi, Gorakhpur in Uttar Pradesh, Bhubaneswar in Odisha, Pondicherry and Agartala in Tripura. In each study site both urban and rural population were included except in Agartala where tribal and rural population was part of the study. In each of rural and urban/tribal area the sample size was 1000 from 25 conveniently selected clusters (40 samples/cluster). In rural/tribal area, individual village and in urban area, municipality ward were considered as cluster. In each cluster, consecutive households from a centre position of the cluster were approached to collect ≥ 40 samples. We collected venous blood with serum separation within 2 hours followed by transport and storage in 2-8 degree Celsius which were analysed by standard qualitative ELISA (WANTAI SARS-CoV-2 total antibody) kit within seven days. Data of basic sociodemographic variables, exposure history, symptoms, and vaccination status were collected.

Result

Total 10110 subjects were recruited and samples collected from total five sites. The proportion of female (55.2%) were little more than male (Table 1).

Whereas according to the different age group, two third of the participants were between 20 years to 60 years (Table 2).

Out of the total 10110 participants, 7474 (73.9%) participants were positive for SARS-CoV-2 antibody. The maximum prevalence were found in urban area of Gorakhpur whereas the lowest prevalence was in rural area of Bhubaneswar (Table 3).

Among the participants aged <18 years the total prevalence was 70.4%
with a maximum being in urban area of Gorakhpur (87.7%). Whereas among the participants aged 18 years or more, the total prevalence was 75.1% with a maximum being 95.6% in urban area of Gorakhpur (Table 4).

The participants gave history of any symptoms faced in last three months. Out of the total seropositive participants, 26.5% had history of any symptoms whereas the 73.4% participants didn’t experience any symptom (Table 5).

Among the participants received at least one dose of COVID vaccine had seropositivity of 79.8% whereas this prevalence was 68.1% among the participants without vaccination (Table 6).

### Table 1: Number of participants recruited in each of rural and urban of all five study sites.

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Delhi (n=2060)</th>
<th>Tripura (n=2000)</th>
<th>Odisha (n=2000)</th>
<th>Gorakhpur (n=2010)</th>
<th>Pondicherry (n=2040)</th>
<th>Total (n=10110)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urban</td>
<td>Rural</td>
<td>Tribal</td>
<td>Rural</td>
<td>Urban</td>
<td>Rural</td>
<td>Urban</td>
</tr>
<tr>
<td>1-4 years</td>
<td>3</td>
<td>10</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>5-9 years</td>
<td>18</td>
<td>44</td>
<td>26</td>
<td>35</td>
<td>25</td>
<td>1</td>
</tr>
<tr>
<td>10-14 years</td>
<td>49</td>
<td>84</td>
<td>50</td>
<td>73</td>
<td>102</td>
<td>1</td>
</tr>
<tr>
<td>15-19 years</td>
<td>37</td>
<td>97</td>
<td>80</td>
<td>65</td>
<td>91</td>
<td>3</td>
</tr>
<tr>
<td>20-29 years</td>
<td>125</td>
<td>209</td>
<td>242</td>
<td>118</td>
<td>185</td>
<td>1</td>
</tr>
<tr>
<td>30-39 years</td>
<td>166</td>
<td>176</td>
<td>180</td>
<td>101</td>
<td>160</td>
<td>1</td>
</tr>
<tr>
<td>40-49 years</td>
<td>202</td>
<td>167</td>
<td>200</td>
<td>155</td>
<td>145</td>
<td>1</td>
</tr>
<tr>
<td>50-59 years</td>
<td>163</td>
<td>107</td>
<td>108</td>
<td>181</td>
<td>114</td>
<td>1</td>
</tr>
<tr>
<td>60-69 years</td>
<td>168</td>
<td>104</td>
<td>129</td>
<td>133</td>
<td>103</td>
<td>1</td>
</tr>
<tr>
<td>70+ years</td>
<td>70</td>
<td>52</td>
<td>86</td>
<td>62</td>
<td>35</td>
<td>1</td>
</tr>
</tbody>
</table>

### Table 2: Number of participants recruited in each age group in rural and urban of all five study sites.

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Delhi (n=2060)</th>
<th>Tripura (n=2000)</th>
<th>Odisha (n=2000)</th>
<th>Gorakhpur (n=2010)</th>
<th>Pondicherry (n=2040)</th>
<th>Total (n=10110)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urban</td>
<td>Rural</td>
<td>Tribal</td>
<td>Rural</td>
<td>Urban</td>
<td>Rural</td>
<td>Urban</td>
</tr>
<tr>
<td>Male</td>
<td>301/419 (71.8)</td>
<td>287/511 (56.2)</td>
<td>379/554 (69.8)</td>
<td>380/511 (74.4)</td>
<td>381/415 (74.6)</td>
<td>334/4529 (73.8)</td>
</tr>
<tr>
<td>Female</td>
<td>448/582 (77.0)</td>
<td>337/548 (61.5)</td>
<td>514/785 (65.5)</td>
<td>352/489 (72.0)</td>
<td>414/437 (94.7)</td>
<td>4130/5581 (74.0)</td>
</tr>
</tbody>
</table>

### Table 3: Sero-prevalence of participants as per sex in rural and urban of all five study sites.

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Delhi</th>
<th>Tripura</th>
<th>Odisha</th>
<th>Gorakhpur</th>
<th>Pondicherry</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urban</td>
<td>Rural</td>
<td>Tribal</td>
<td>Rural</td>
<td>Urban</td>
<td>Rural</td>
<td>Urban</td>
</tr>
<tr>
<td>Male</td>
<td>68/73.9</td>
<td>115/60.8</td>
<td>39/32.2</td>
<td>69/63.3</td>
<td>98/64.1</td>
<td>77/46.1</td>
</tr>
<tr>
<td>Female</td>
<td>681/74.9</td>
<td>509/58.5</td>
<td>322/59.6</td>
<td>824/66.9</td>
<td>634/74.8</td>
<td>474/59.6</td>
</tr>
</tbody>
</table>

### Table 4: Sero-prevalence among <18 years and ≥ 18 years in rural and urban of all five study sites.

Discussion and Conclusion

The evidence showed that a major portion of the population was infected across all age throughout the nation. According to a meta-analysis, the pooled prevalence after the second wave in India was 69.2% which was similar to our evidence whereas another large study among 2433 participants reported 71.5% sero-prevalence [4,5]. The prevalence was relatively more among population of the urban area due to its inherited pattern of transmission in urbanized area. On the other side this prevalence was similar in both sex, both the age group (<18 years and ≥ 18 years). The evidence was similar to the two community based study in South India showing the similar prevalence in both sex and age group [6,7]. The majority of the seropositive population was asymptomatic according to our study which is similar to the study by Dayanand et al. [5]. Among the participants having history of COVID vaccination the pooled prevalence was relatively higher than those without history of vaccination though this difference were not seen among the participants of urban areas.

Conflicts of Interest

Nil.

Declaration

Source of funding

This work was supported by a research grant (Ref No: 2020/1085497, Purchase Order: 202630166) from the WHO Country Office, New Delhi 110016, India.

Previous presentation/submission

Part of the data at the preliminary stage has been published at Journal of Family Medicine and Primary Care: June 2022 - Volume 11 - Issue 6 - p 2816-2823 (doi: 10.4103/jfmpc.jfmpc_2274_21)

Acknowledgement

We express our gratitude to the WHO Country Office, India team especially Dr Mohammad Ahmad (National Professional Officer, WHO) and Dr Anisur Rahman (Health Emergencies and Research Officer, WHO) for their constant support and supervision. We thank to all the participants who had given consent to us to conduct this large sero-epidemiogical research study in the general population, in which COVID-19 virus infection had been reported.

References


